Topic: Jeffrey Cohen
Executives. . Karen Peterson - Investor Relations Specialist. . Bob Butchofsky - President and Chief Executive Officer. . Suzanne Cadden - Vice...
Executives. . Karen Peterson - Investor Relations Specialist. . Bob Butchofsky - President and CEO. . Cameron Nelson - Chief Financial Officer....
Adults need them, too, and while vaccination rates are increasing, there's definitely room for improvement, according to public health experts.. Thanks to vaccines, ''we see only a fraction of the disease, death and suffering'' as in years past, says Susan J ...
QLT Inc. (QLTI) Q3 2010 Earnings Call Transcript November 03, 2010 8:30 am ET. Presenting today is Bob Butchofsky, our President and CEO, and Cameron Nelson, our Chief Financial Officer. Turning briefly to Visudyne, as I mentioned earlier, end-user sales in ...
Executives. . Karen Peterson - IR. . Bob Butchofsky - President and CEO. . Cameron Nelson - VP, Finance and CFO. . Dipak Panigrahi - SVP, Research...
Metropolitan Health Networks Inc. (MDF) Q1 2010 Earnings Call May 04, 2010 11:00 am ET. Such statements which include estimated financial information or results are based on management's current expectations and are subject to a number of factors and uncertainties ...
In patients with relapsing-remitting multiple sclerosis, once-daily oral fingolimod is more effective than once-weekly intramuscular interferon injection at preventing relapses, according to a study published online Jan. 20 in the New England Journal of Medicine.. Jeffrey A. Cohen, M.D., of the ...
Cantel Medical Corp. (CMN) F1Q10 Earnings Call December 09, 2009 11:00 am ET. (Operator Instructions) It is now my pleasure to introduce our host, Andrew Krakauer, President and CEO of Cantel Medical Corp. With me today on our call are Chuck ...
Rosh Hashanah, the Jewish New Year, begins tonight at sundown. To find out, I consulted Jeffrey M. Cohen's 1,001 Questions and Answers on Rosh Hashanah and Yom Kippur (thank you, Google Books), where I also found answers to questions I ...
significantly better than a leading current treatment. * Additional data from a long-term extension of FTY720 Phase II trial show sustained low relapse rates and no significant change in safety profile between three and four years[1]. New Phase III results presented at ...